10-Q quarterly report · filed Nov 4, 2026

Lyell Immunopharma Inc (LYEL) Q3 2026 10-Q Quarterly Report

Short answer

Lyell Immunopharma Inc (LYEL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3,000 (down 80.0% year over year) with net income of −$46M.

Q3 2026 key financials · XBRL

Revenue
$3,000
−80.0% YoY · −25.0% QoQ
Net income
−$46M
−17.2% YoY · −1.7% QoQ
Operating margin
-1609833.3%
EPS (diluted)
−$1.88
+4.1% YoY · +3.6% QoQ

Source: XBRL data from the Lyell Immunopharma Inc (LYEL) Q3 2026 10-Q on SEC EDGAR. USD.

Lyell Immunopharma Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no approved products or product sales
  • Operating loss $48.3M vs $37.3M YoY, net loss $45.5M vs $38.8M
  • R&D expense $40.9M vs $28.2M, driven by increased clinical trial activity
  • Cash, equivalents and marketable securities $194.0M; operating cash outflow $107.0M
  • Guidance: liquidity sufficient for at least 12 months; additional capital needed, with clinical and manufacturing costs rising

Risk Factors

  • Newly added trade-policy risk: April 2026 tariffs up to 100% on certain imported pharmaceuticals, APIs and key starting materials
  • Most materially updated capital risk: November 2026 Securities Purchase Agreement is the only committed external funding source
  • Regulatory compliance risk: cGMP or cGTP failures could trigger clinical holds, production suspension, recalls or approval withdrawal
  • Near-term trial risk: Competitor liso-cel and axi-cel availability may reduce enrollment in the PiNACLE-H2H trial
  • Financial dilution risk: ICT may receive up to 1.85 million additional shares, including 1.1 million issued in July 2026

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.